Back to Browse Journals » Patient Preference and Adherence » Volume 2

Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia

Authors Haya Ascher-Svanum, Baojin Zhu, Douglas E Faries, Jonathan P Lacro, Christian R Dolder, Xiaomei Peng

Published 13 March 2008 Volume 2008:2 Pages 67—77

DOI http://dx.doi.org/10.2147/PPA.S2940

Haya Ascher-Svanum1, Baojin Zhu1, Douglas E Faries1, Jonathan P Lacro2, Christian R Dolder3, Xiaomei Peng1

1Eli Lilly and Company, Outcomes Research, Indianapolis, IN, USA; 2VA San Diego Health Care System and Department of Psychiatry, University of California, San Diego, CA, USA; 3Wingate University School of Pharmacy, Wingate, NC, USA

Objective: To compare adherence and persistence to typical versus atypical antipsychotics and between specific atypical agents in the usual care of schizophrenia and to examine the association between adherence and persistence.

Method: Data were drawn from a 3-year prospective, nonrandomized, noninterventional study of schizophrenia conducted during 1997–2003. Initiators on haloperidol, risperidone, olanzapine, quetiapine, and clozapine with at least 1 year of follow-up were included (n = 878). Adherence (Medication Possession Ratio, MPR) and persistence (time to all-cause medication discontinuation) were assessed using medical record prescription information. Analyses employed multivariate statistics adjusted for group differences.

Results: Overall, 58% of the patients were deemed adherent (MPR >80%). Adherence rates were higher: for atypical (59.4%) than typical antipsychotics (34.5%, p < 0.001), for clozapine (77%) than each comparator excluding olanzapine (p < 0.01), and for olanzapine (64%) than risperidone (57%, p = 0.027) and quetiapine (52%, p = 0.019). Differences between risperidone and quetiapine were not statistically significant. Adherence and persistence were highly correlated (r = 0.957, p < 0.001).

Conclusion: In the usual care of schizophrenia, medication adherence and persistence appear to be highly correlated and to significantly differ between typical and atypical antipsychotics and among atypical agents. The choice of antipsychotic may play a meaningful role in patients’ adherence to and persistence with antipsychotic medications.

Keywords: adherence, persistence, schizophrenia, antipsychotics

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other articles by this author:

Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia

Ascher-Svanum H, Brnabic AJM, Lawson AH, Kinon BJ, Stauffer VL, Feldman PD, Kelin K

Neuropsychiatric Disease and Treatment 2012, 8:113-118

Published Date: 15 March 2012

Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia

Xiaomei Peng, Haya Ascher-Svanum, Douglas Faries et al

ClinicoEconomics and Outcomes Research 2011, 3:9-14

Published Date: 11 January 2011

Readers of this article also read:

How do patients with a Turkish background evaluate their medical care in Germany? An observational study in primary care

Goetz K, Bungartz J, Szecsenyi J, Steinhaeuser J

Patient Preference and Adherence 2015, 9:1573-1579

Published Date: 3 November 2015

Effect of liposomal fluidity on skin permeation of sodium fluorescein entrapped in liposomes

Subongkot T, Ngawhirunpat T

International Journal of Nanomedicine 2015, 10:4581-4592

Published Date: 17 July 2015

Volasertib for AML: clinical use and patient consideration

Hao Z, Kota V

OncoTargets and Therapy 2015, 8:1761-1771

Published Date: 17 July 2015

Stability and toxicity of empty or gene-loaded lipopolysaccharide-amine nanopolymersomes

Wang QM, Chen Y, Wang LC, Zhang XC, Huang HZ, Teng W

International Journal of Nanomedicine 2015, 10:597-608

Published Date: 13 January 2015

Economic and outcomes consequences of TachoSil®: a systematic review

Colombo GL, Bettoni D, Di Matteo S, Grumi C, Molon C, Spinelli D, Mauro G, Tarozzo A, Bruno GM

Vascular Health and Risk Management 2014, 10:569-576

Published Date: 10 September 2014

CYP19A1 single nucleotide polymorphism associations with CYP19A1, NFκB1, and IL6 gene expression in human normal colon and normal liver samples

Penney RB, Lundgreen A, Yao-Borengasser A, Edavana VK, Williams S, Dhakal I, Wolff RK, Kadlubar S, Slattery ML

Pharmacogenomics and Personalized Medicine 2014, 7:163-171

Published Date: 14 July 2014

Stability and antimicrobial effect of amikacin-loaded solid lipid nanoparticles

Solmaz Ghaffari, Jaleh Varshosaz, Afrooz Saadat, et al

International Journal of Nanomedicine 2011, 6:35-43

Published Date: 16 December 2010

Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence

Katarina Kelin, Alan JM Brnabic, Richard Newton, et al

Patient Preference and Adherence 2010, 4:301-311

Published Date: 11 August 2010